we exceeded our adjusted earnings per share expectations for the fourth quarter in a row delivering $num-one adjusted earnings per share in the final quarter of year-six and $num-two adjusted earnings per share for the full year.
as karen noted earlier, we are maintaining our full year adjusted earnings per share guidance range of $num-one to $num-two.
at this early stage of the year, we are maintaining our full year year-seven adjusted earnings per share guidance of $num-one to $num-two.
we reported adjusted operating income of num-one billion and adjusted earnings per share of $num-two, representing an increase of num-three% and num-four% versus prior year, respectively.
for the full year year-six, cvs health grew adjusted revenue by num-one% to $num-two billion.
this represents num-one% to num-two% growth versus our revised year-six, adjusted earnings per share baseline of $num-three.
we delivered adjusted operating income of num-one billion and adjusted earnings per share of $num-two, up approximately num-three% and num-four% year over year, respectively.
capital expenditures are expected to be in the range of $num-one billion to $num-two billion as we invest in technology and digital enhancements to improve the consumer experience, as well as our community locations.
and we are updating our guidance range to $num-one billion to $num-two billion, reflecting the improved cash flow results for year-six.
we generated strong cash flow from operations of nearly $num-one billion for the full year, exceeding our most recent guidance of at least $num-two billion.
we delivered adjusted operating income of $num-one billion, up num-two% year over year.
for full year year-six, we reported total adjusted revenues of num-one billion, an increase of num-two% versus prior year, reflecting robust growth across all business segments.
for year-seven, we forecast num-one% to num-two% revenue growth and num-three% to num-four% adjusted operating income growth.
and we increased adjusted earnings per share by num-one%.
in year-seven, we expect vaccine volumes to decline approximately num-one% to num-two% and in-store diagnostic testing volumes to decline num-three% to num-four% compared to year-six.
this now implies retail revenue to be plus or minus num-one% versus prior year, and a low num-two% decline in adjusted operating income growth.